title: Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage.
abstract: OBJECTIVE
  One hundred consecutive patients with recurrent or refractory acute variceal hemorrhage treated with a transjugular intrahepatic portosystemic shunt (TIPS) from June 1990 to June 1993 at Oregon Health Sciences University or the Portland Veterans Affairs Medical Center were evaluated to assess shunt patency and clinical outcome, including complications of TIPS, rebleeding, and survival.
  
  
  METHODS
  Success of shunt placement, reduction in portal pressure, complications, survival, recurrent hemorrhage, severity of ascites, hepatic encephalopathy before and after TIPS, and shunt patency were assessed in each patient.
  
  
  RESULTS
  The mean follow-up period was 17.7 months (range, 0.1-56.7 months). TIPS was successfully completed in all patients, with a mean reduction in portosystemic gradient from 24 to 11 mm Hg. Major complications occurred in 11 patients, including one death. Survival after TIPS was 85% at 30 days, 71% at 1 yr, and 56% at 2 yr. Variceal bleeding stopped within 24 hours after TIPS in all eight patients with active hemorrhage. Recurrent variceal hemorrhage occurred in 18 patients at a mean of 4.3 months (range, 1-713 days) after TIPS. The cumulative rate of recurrent variceal bleeding was 20% at 1 yr and 25% at 2 yr after TIPS. Recurrent variceal bleeding was associated with shunt stenosis or occlusion in all patients with endoscopically documented variceal hemorrhage, which was successfully managed by reopening obstructed shunts and performing variceal embolization. The prevalence of ascites was significantly reduced among surviving patients evaluated 3 months after TIPS (67 vs 25%, p < 0.005). Three months after TIPS, the incidence of new or worsening hepatic encephalopathy was 20%, but encephalopathy improved in an equal proportion of patients. Seventy-three of 77 (95%) shunts examined for patency were open at the last follow-up examination. However, most shunts required intervention to maintain patency, and only 48% (37 of 77) were primarily patent at a mean of 168 days (range, 2-538 days) of follow-up. Shunt stenosis or occlusion, as determined by venography, became increasingly frequent with longer follow-up (52% at 3-9 months and 70% at 9-15 months).
  
  
  CONCLUSIONS
  TIPS is effective in lowering elevated portal pressures in patients with refractory variceal hemorrhage, has acceptable postprocedure complication and mortality rates, ameliorates ascites, and in, a minority of patients, worsens encephalopathy. Shunt stenosis occurs in the majority of patients but can be effectively treated by interventional techniques to maintain patency. The incidence of recurrent variceal hemorrhage is low and is associated with shunt stenosis or occlusion.
authors.affiliation: Department of Medicine, Oregon Health Sciences University, Portland 97201, USA.
authors.forename: G
authors.initials: G
authors.lastname: Sahagun
authors.forename: K G
authors.initials: KG
authors.lastname: Benner
authors.forename: R
authors.initials: R
authors.lastname: Saxon
authors.forename: R E
authors.initials: RE
authors.lastname: Barton
authors.forename: J
authors.initials: J
authors.lastname: Rabkin
authors.forename: F S
authors.initials: FS
authors.lastname: Keller
authors.forename: J
authors.initials: J
authors.lastname: Rosch
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001201:Ascites / Q000601:surgery; D002423:Cause of Death; D003251:Constriction, Pathologic / Q000209:etiology / Q000628:therapy; D004621:Embolization, Therapeutic; D004932:Esophageal and Gastric Varices / Q000601:surgery* / Q000628:therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006471:Gastrointestinal Hemorrhage / Q000601:surgery* / Q000628:therapy; D006501:Hepatic Encephalopathy / Q000601:surgery; D006801:Humans; D006975:Hypertension, Portal / Q000601:surgery; D015994:Incidence; D008297:Male; D008875:Middle Aged; D017082:Portal Pressure; D019168:Portasystemic Shunt, Transjugular Intrahepatic / Q000009:adverse effects; D015995:Prevalence; D011446:Prospective Studies; D012008:Recurrence; D015996:Survival Rate; D016896:Treatment Outcome; D014654:Vascular Patency